AP NEWS
Click to copy
Press release content from Business Wire. The AP news staff was not involved in its creation.
Click to copy
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Personal Genome Diagnostics CE Marks Liquid Biopsy Test

March 14, 2019

BALTIMORE--(BUSINESS WIRE)--Mar 14, 2019--Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics, today announced that it has applied the CE mark to PGDx elio™ plasma resolve. It is the first kitted plasma-based NGS oncology test to have that certification, enabling greater access to genomic testing for cancer patients in Europe.

PGDx elio™ plasma resolve is a qualitative in vitro diagnostic test that uses targeted high throughput, parallel-sequencing technology to detect single nucleotide variants (SNVs), small insertion/deletions (indels), amplifications, rearrangements, and microsatellite instability (MSI) in a broad multi-gene panel in circulating cell-free DNA (cfDNA) isolated from plasma samples. It encompasses several clinically actionable variants across tumor types, enabling more informed treatment decisions.

“We are extremely proud of this important milestone,” said Doug Ward, Chief Executive Officer. “Our vision is to improve clinical insight, speed of results, and health economics by delivering a portfolio of regulated tissue-based and liquid biopsy genomic products to laboratories worldwide. The CE mark of PGDx elio™ plasma resolve allows us to bring this product to Europe, providing greater access to patients who could benefit from genomic testing, particularly those who cannot provide tissue samples.”

CE certification indicates conformity with health, safety, and environmental protection standards for products sold within the European Economic Area (EEA). With the CE-mark, PGDx aims to advance strategic partnerships with molecular laboratory and oncology leaders in the European market to enable genomic testing closer to where patients are treated, expanding the potential of precision medicine.

The PGDx elio™ plasma resolve previously received Breakthrough Device designation from The Center for Devices and Radiological Health (CDRH) of the U.S. Food and Drug Administration (FDA) in July of 2018.

About Personal Genome Diagnostics
Personal Genome Diagnostics (PGDx) empowers the fight against cancer by unlocking actionable information from the genome. We are committed to developing a portfolio of regulated tissue-based and liquid biopsy genomic products for laboratories worldwide. PGDx was established by researchers from Johns Hopkins University who are pioneers in cancer genome sequencing and liquid biopsy technologies. For additional information, visit www.PersonalGenome.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20190314005046/en/

CONTACT: PGDx Corporate:

Megan Bailey

Vice President, Marketing

520-820-8710

mbailey@pgdx.com

W2O Group:

Peter Duckler

Director, Media

773-343-3068

pduckler@w2ogroup.com

KEYWORD: UNITED STATES EUROPE NORTH AMERICA MARYLAND

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY ONCOLOGY PHARMACEUTICAL OTHER HEALTH RESEARCH SCIENCE

SOURCE: Personal Genome Diagnostics Inc.

Copyright Business Wire 2019.

PUB: 03/14/2019 06:45 AM/DISC: 03/14/2019 06:45 AM

http://www.businesswire.com/news/home/20190314005046/en

All contents © copyright 2019 The Associated Press. All rights reserved.